Health and wellness products company USANA Health Sciences (NYSE: USNA) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 5.4% year on year to $223 million. On the other hand, the company’s full-year revenue guidance of $962.5 million at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP loss of $0.07 per share was significantly below analysts’ consensus estimates.
Is now the time to buy USANA? Find out by accessing our full research report, it’s free.
USANA (USNA) Q2 CY2026 Highlights:
- Revenue: $223 million vs analyst estimates of $235 million (5.4% year-on-year decline, 5.1% miss)
- Adjusted EPS: -$0.07 vs analyst estimates of $0.43 (significant miss)
- Adjusted EBITDA: $27.85 million vs analyst estimates of $23.61 million (12.5% margin, 18% beat)
- The company reconfirmed its revenue guidance for the full year of $962.5 million at the midpoint
- Management reiterated its full-year Adjusted EPS guidance of $2.12 at the midpoint
- EBITDA guidance for the full year is $105 million at the midpoint, in line with analyst expectations
- Market Capitalization: $421.7 million
Company Overview
Going to market with a direct selling model rather than through traditional retailers, USANA Health Sciences (NYSE: USNA) manufactures and sells nutritional, personal care, and skincare products.
Revenue Growth
A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years.
With $913.1 million in revenue over the past 12 months, USANA is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.
As you can see below, USANA struggled to generate demand over the last three years. Its sales dropped by 1.2% annually, a poor baseline for our analysis.
This quarter, USANA missed Wall Street’s estimates and reported a rather uninspiring 5.4% year-on-year revenue decline, generating $223 million of revenue.
Looking ahead, sell-side analysts expect revenue to grow 6.2% over the next 12 months, an acceleration versus the last three years. This projection is above the sector average and implies its newer products will fuel better top-line performance.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Cash Is King
If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.
USANA has shown mediocre cash profitability relative to peers over the last two years, giving the company fewer opportunities to return capital to shareholders. Its free cash flow margin averaged 2.9%, below what we’d expect for a consumer staples business.
Key Takeaways from USANA’s Q2 Results
We were impressed by how significantly USANA blew past analysts’ EBITDA expectations this quarter. We were also glad its full-year revenue guidance exceeded Wall Street’s estimates. On the other hand, its revenue missed and its EPS fell short of Wall Street’s estimates. Overall, this quarter could have been better. The stock traded down 19.2% to $18.41 immediately after reporting.
Is USANA an attractive investment opportunity at the current price? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).
